Heart Valve Replacement Procedures Market - Strategic Insights and Forecasts (2026-2031)

Description

The Global Heart Valve Replacement Procedures Market is forecast to grow at a CAGR of 7.2%, reaching USD 26.7 billion in 2031 from USD 18.9 billion in 2026.

The global heart valve replacement procedures market is witnessing strong growth due to the increasing prevalence of valvular heart diseases, rising aging populations, and growing adoption of minimally invasive cardiac procedures. Heart valve replacement procedures are widely used for the treatment of aortic stenosis, mitral valve regurgitation, and other structural heart disorders that affect normal blood flow within the heart. Healthcare providers are increasingly adopting advanced transcatheter and surgical valve replacement technologies to improve patient outcomes, reduce recovery time, and lower procedural risks. Expanding healthcare infrastructure, increasing cardiovascular screening programs, and growing awareness regarding early treatment of structural heart diseases are further supporting market growth globally.

Market Drivers

The rising burden of valvular heart diseases remains a major factor driving the heart valve replacement procedures market. Increasing incidence of aortic stenosis, rheumatic heart disease, and degenerative valve disorders among aging populations is creating strong demand for effective treatment procedures. Lifestyle-related risk factors such as hypertension, obesity, and diabetes are also contributing to the growing prevalence of structural heart conditions.

Growing preference for minimally invasive procedures is another important market driver. Transcatheter heart valve replacement procedures offer shorter hospital stays, faster recovery, and lower complication risks compared to traditional open-heart surgery. Increasing patient eligibility for minimally invasive interventions is expanding procedural volumes across hospitals and specialty cardiac centers.

Technological advancements in heart valve devices and imaging systems are further accelerating market growth. Transcatheter aortic valve replacement technologies, next-generation bioprosthetic valves, and advanced cardiac imaging systems are improving procedural precision and long-term treatment outcomes. Integration of three-dimensional imaging and AI-assisted procedural planning tools is also enhancing clinical decision-making and procedural efficiency.

Increasing healthcare expenditure and growing investment in specialized cardiac care infrastructure across emerging economies are further supporting market penetration and accessibility to advanced valve replacement procedures.

Market Restraints

High procedural costs and expensive cardiac implant technologies remain major challenges for healthcare providers and patients. Advanced transcatheter valve systems, imaging equipment, and hybrid operating room infrastructure require significant capital investment, limiting accessibility in cost-sensitive healthcare markets.

Risk of procedural complications such as bleeding, stroke, valve leakage, and infection may also affect patient outcomes and treatment adoption. Regulatory approval requirements for implantable cardiac devices can further increase product development timelines and operational costs for manufacturers.

Limited availability of highly skilled cardiac surgeons and interventional cardiologists in certain regions may restrict market expansion and access to advanced structural heart procedures.

Technology and Segment Insights

Transcatheter aortic valve replacement procedures continue to represent a rapidly growing segment due to increasing clinical adoption and expanding patient eligibility criteria. Surgical heart valve replacement procedures also maintain significant market demand for complex and high-risk cardiovascular cases.

Bioprosthetic heart valves are witnessing strong growth because of their durability and lower requirement for long-term anticoagulation therapy. Mechanical heart valves continue to be used for younger patient populations requiring long-lasting implant solutions.

Advanced imaging technologies, including three-dimensional echocardiography and CT-guided procedural planning systems, are improving procedural precision and patient assessment. Hospitals and specialty cardiac centers remain the dominant end-user segment due to their advanced surgical infrastructure and growing cardiovascular patient volumes.

Competitive and Strategic Outlook

The market includes major cardiovascular device manufacturers, structural heart technology companies, and healthcare providers competing through innovation and advanced treatment solutions. Companies are investing in next-generation transcatheter valve systems, minimally invasive procedural technologies, and AI-assisted imaging platforms to strengthen competitive positioning.

Strategic partnerships, clinical collaborations, and acquisitions are becoming increasingly common across the industry. Manufacturers are also focusing on expanding global distribution networks, physician training programs, and product accessibility in emerging healthcare markets.

Conclusion

The global heart valve replacement procedures market is expected to witness substantial growth through 2031, supported by rising valvular heart disease prevalence, increasing adoption of minimally invasive cardiac procedures, and continuous advancements in structural heart technologies. Transcatheter valve replacement systems, AI-assisted imaging solutions, and advanced bioprosthetic valves will continue to shape market development. Companies focusing on innovation, procedural efficiency, and accessible cardiovascular treatment solutions are likely to strengthen their long-term market position.

Key Benefits of this Report

Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024 and forecast data from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

Product Code: KSI-008679

1. Executive Summary

1.1 Market Snapshot
- 1.1.1 Overview of Global Heart Valve Replacement Procedures Market
- 1.1.2 Key Market Highlights
- 1.1.3 Procedure Volume Analysis
- 1.1.4 Market Size and Forecast Summary
- 1.1.5 Key Growth Drivers
- 1.1.6 Key Challenges and Risk Factors
- 1.1.7 Strategic Opportunities
1.2 Executive Insights
- 1.2.1 Shift from Surgical to Transcatheter Procedures
- 1.2.2 Technological Advancements in Bioprosthetic Valves
- 1.2.3 Emerging Role of Minimally Invasive Interventions
- 1.2.4 Hospital and Specialty Cardiac Center Adoption Trends
- 1.2.5 Reimbursement and Access Trends

2. Disease & Epidemiology Analysis

2.1 Overview of Heart Valve Diseases
- 2.1.1 Aortic Valve Disease
- 2.1.2 Mitral Valve Disease
- 2.1.3 Tricuspid Valve Disease
- 2.1.4 Pulmonary Valve Disease
2.2 Etiology and Risk Factors
- 2.2.1 Degenerative Valve Disease
- 2.2.2 Rheumatic Heart Disease
- 2.2.3 Congenital Valve Disorders
- 2.2.4 Infective Endocarditis
- 2.2.5 Age-Associated Calcific Valve Disease
2.3 Disease Burden and Epidemiology
- 2.3.1 Global Prevalence of Valvular Heart Diseases
- 2.3.2 Incidence of Severe Aortic Stenosis
- 2.3.3 Prevalence of Mitral Regurgitation
- 2.3.4 Epidemiology by Age Group
- 2.3.5 Epidemiology by Gender
- 2.3.6 High-Risk Patient Population Analysis
2.4 Clinical Diagnosis and Patient Assessment
- 2.4.1 Echocardiography-Based Diagnosis
- 2.4.2 CT and MRI Imaging Assessment
- 2.4.3 Cardiac Catheterization and Hemodynamic Evaluation
- 2.4.4 Surgical Risk Stratification Models
2.5 Treatment Eligibility Analysis
- 2.5.1 Surgical Candidates
- 2.5.2 High-Risk and Inoperable Patients
- 2.5.3 Intermediate-Risk Patients
- 2.5.4 Elderly Patient Population Assessment

3. Market Dynamics

3.1 Market Drivers
- 3.1.1 Rising Geriatric Population
- 3.1.2 Increasing Burden of Valvular Heart Diseases
- 3.1.3 Expanding Adoption of Transcatheter Valve Therapies
- 3.1.4 Technological Advancements in Tissue Valves
- 3.1.5 Growth in Structural Heart Intervention Centers
3.2 Market Restraints
- 3.2.1 High Procedure Costs
- 3.2.2 Limited Access in Developing Markets
- 3.2.3 Procedural Complications and Device Failures
- 3.2.4 Stringent Regulatory Requirements
3.3 Market Opportunities
- 3.3.1 Expansion into Low-Risk Patient Populations
- 3.3.2 Growth Potential in Emerging Economies
- 3.3.3 Next-Generation Transcatheter Mitral and Tricuspid Devices
- 3.3.4 AI and Imaging Integration in Structural Heart Procedures
3.4 Market Challenges
- 3.4.1 Skilled Workforce Shortage
- 3.4.2 Long-Term Valve Durability Concerns
- 3.4.3 Reintervention Risks
- 3.4.4 Reimbursement Variability Across Markets
3.5 Porter's Five Forces Analysis
3.6 PESTLE Analysis
3.7 Value Chain Analysis
3.8 Pricing Analysis
3.9 Procedure Adoption Trends

4. Commercial & Market Access

4.1 Reimbursement Landscape
- 4.1.1 Public Reimbursement Models
- 4.1.2 Private Insurance Coverage
- 4.1.3 DRG and Bundled Payment Systems
- 4.1.4 Coverage for TAVR and SAVR Procedures
4.2 Market Access Challenges
- 4.2.1 Hospital Procurement Barriers
- 4.2.2 Cost-Effectiveness Evaluation
- 4.2.3 Access in Emerging Markets
4.3 Healthcare Infrastructure Assessment
- 4.3.1 Availability of Hybrid Operating Rooms
- 4.3.2 Structural Heart Program Expansion
- 4.3.3 Cardiac Surgery Center Capacity
4.4 Stakeholder Analysis
- 4.4.1 Hospitals and Cardiac Centers
- 4.4.2 Interventional Cardiologists
- 4.4.3 Cardiothoracic Surgeons
- 4.4.4 Payers and Government Agencies

5. Innovation & Pipeline Landscape

5.1 Innovation Trends in Heart Valve Replacement
- 5.1.1 Transcatheter Aortic Valve Replacement (TAVR) Innovations
- 5.1.2 Transcatheter Mitral Valve Replacement (TMVR) Innovations
- 5.1.3 Transcatheter Tricuspid Valve Replacement (TTVR) Innovations
- 5.1.4 Sutureless and Rapid Deployment Valves
- 5.1.5 Advanced Bioprosthetic Materials
- 5.1.6 Imaging-Guided Procedural Technologies
- 5.1.7 AI-Assisted Structural Heart Planning
5.2 Pipeline Landscape by Development Stage
- 5.2.1 Preclinical Devices and Technologies
- 5.2.2 Early Feasibility Studies
- 5.2.3 Pivotal Clinical Trials
- 5.2.4 Commercial Expansion Studies
5.3 Pipeline Analysis by Valve Type
- 5.3.1 Aortic Valve Replacement Pipeline
- 5.3.2 Mitral Valve Replacement Pipeline
- 5.3.3 Tricuspid Valve Replacement Pipeline
- 5.3.4 Pulmonary Valve Replacement Pipeline
5.4 Pipeline Analysis by Modality
- 5.4.1 Balloon-Expandable Valve Systems
- 5.4.2 Self-Expanding Valve Systems
- 5.4.3 Mechanical Valve Technologies
- 5.4.4 Tissue-Engineered Valve Platforms
5.5 Clinical Trial Landscape
- 5.5.1 Active Phase I Trials
- 5.5.2 Active Phase II Trials
- 5.5.3 Active Phase III Trials
- 5.5.4 Post-Market Clinical Studies

6. Treatment Landscape

6.1 Current Treatment Algorithm
- 6.1.1 Medical Management
- 6.1.2 Surgical Valve Repair
- 6.1.3 Surgical Valve Replacement
- 6.1.4 Transcatheter Valve Replacement Procedures
6.2 Surgical Heart Valve Replacement (SAVR)
- 6.2.1 Mechanical Valves
- 6.2.2 Bioprosthetic Valves
- 6.2.3 Minimally Invasive Surgical Procedures
6.3 Transcatheter Heart Valve Replacement
- 6.3.1 TAVR/TAVI Procedures
- 6.3.2 TMVR Procedures
- 6.3.3 TTVR Procedures
- 6.3.4 Valve-in-Valve Procedures
6.4 Comparative Clinical Analysis
- 6.4.1 TAVR vs SAVR Outcomes
- 6.4.2 Procedure Success Rates
- 6.4.3 Complication Analysis
- 6.4.4 Long-Term Durability Analysis
6.5 Clinical Guidelines and Recommendations
- 6.5.1 ACC/AHA Guidelines
- 6.5.2 ESC/EACTS Guidelines
- 6.5.3 Asian Pacific Society Recommendations

7. Global Heart Valve Replacement Procedures Market Size & Forecast

7.1 Global Market Overview
- 7.1.1 Historical Market Size Analysis
- 7.1.2 Current Market Valuation
- 7.1.3 Forecast Market Size (2026-2031)
- 7.1.4 CAGR Analysis
7.2 Market Size by Procedure Type
- 7.2.1 Surgical Valve Replacement
- 7.2.2 Transcatheter Valve Replacement
7.3 Market Size by Valve Type
- 7.3.1 Aortic Valve Replacement
- 7.3.2 Mitral Valve Replacement
- 7.3.3 Tricuspid Valve Replacement
- 7.3.4 Pulmonary Valve Replacement
7.4 Market Size by End User
- 7.4.1 Hospitals
- 7.4.2 Specialty Cardiac Centers
- 7.4.3 Ambulatory Surgical Centers
7.5 Market Forecast Assumptions and Scenario Analysis
- 7.5.1 Optimistic Scenario
- 7.5.2 Base Case Scenario
- 7.5.3 Conservative Scenario

8. Global Heart Valve Replacement Procedures Market Segmentation

8.1 By Procedure Type
- 8.1.1 Surgical Heart Valve Replacement
- 8.1.2 Transcatheter Heart Valve Replacement
8.2 By Valve Type
- 8.2.1 Aortic Valve
- 8.2.2 Mitral Valve
- 8.2.3 Tricuspid Valve
- 8.2.4 Pulmonary Valve
8.3 By Device Type
- 8.3.1 Mechanical Heart Valves
- 8.3.2 Tissue/Bioprosthetic Heart Valves
- 8.3.3 Transcatheter Heart Valves
8.4 By End User
- 8.4.1 Hospitals
- 8.4.2 Specialty Clinics
- 8.4.3 Ambulatory Surgical Centers

9. Geographical Analysis (Regional Level)

9.1 North America
- 9.1.1 Market Size and Forecast
- 9.1.2 Demand Drivers
- 9.1.3 Regional Regulatory Overview
- 9.1.4 Competitive Intensity
9.2 Europe
- 9.2.1 Market Size and Forecast
- 9.2.2 Demand Drivers
- 9.2.3 Regional Regulatory Overview
- 9.2.4 Competitive Intensity
9.3 Asia-Pacific
- 9.3.1 Market Size and Forecast
- 9.3.2 Demand Drivers
- 9.3.3 Regional Regulatory Overview
- 9.3.4 Competitive Intensity
9.4 Latin America
- 9.4.1 Market Size and Forecast
- 9.4.2 Demand Drivers
- 9.4.3 Regional Regulatory Overview
- 9.4.4 Competitive Intensity
9.5 Middle East & Africa
- 9.5.1 Market Size and Forecast
- 9.5.2 Demand Drivers
- 9.5.3 Regional Regulatory Overview
- 9.5.4 Competitive Intensity

10. Key Countries Analysis

10.1 United States
- 10.1.1 Market Size
- 10.1.2 Epidemiology Overview
- 10.1.3 FDA Regulatory Framework
- 10.1.4 Reimbursement Landscape
- 10.1.5 Key Companies and Product Presence
10.2 Canada
- 10.2.1 Market Size
- 10.2.2 Epidemiology Overview
- 10.2.3 Regulatory Framework
- 10.2.4 Reimbursement Landscape
- 10.2.5 Key Companies and Product Presence
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
10.9 Japan
10.10 India
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa
- 10.3.1 to 10.16.5 (Applicable to Each Country)

Market Size

Epidemiology Overview

Regulatory Framework

Reimbursement Landscape

Key Companies and Product Presence

11. Regulatory & Policy Landscape

11.1 United States Regulatory Framework
- 11.1.1 FDA Premarket Approval (PMA) Process
- 11.1.2 FDA Device Classification
- 11.1.3 Post-Market Surveillance Requirements
11.2 Europe Regulatory Framework
- 11.2.1 European Medical Device Regulation (EU MDR)
- 11.2.2 CE Marking Requirements
- 11.2.3 EUDAMED and Clinical Evaluation
11.3 Japan Regulatory Framework
- 11.3.1 PMDA Approval Pathways
- 11.3.2 Reimbursement and HTA Assessment
11.4 India Regulatory Framework
- 11.4.1 CDSCO Medical Device Regulations
- 11.4.2 Import and Registration Requirements
11.5 China Regulatory Framework
- 11.5.1 NMPA Approval Pathways
- 11.5.2 Local Clinical Trial Requirements
11.6 Health Technology Assessment and Policy Trends
- 11.6.1 Cost-Effectiveness Evaluation
- 11.6.2 Real-World Evidence Requirements
- 11.6.3 Procurement and Tender Systems

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Product Portfolio Comparison
12.4 Strategic Developments
- 12.4.1 Mergers and Acquisitions
- 12.4.2 Partnerships and Collaborations
- 12.4.3 Regulatory Approvals
- 12.4.4 Product Launches
- 12.4.5 Clinical Trial Advancements
12.5 SWOT Analysis
12.6 Competitive Positioning Matrix

13. Company Profiles

13.1 Edwards Lifesciences
- 13.1.1 Company Overview
- 13.1.2 Approved Products

SAPIEN 3 Transcatheter Heart Valve

SAPIEN 3 Ultra RESILIA Valve

INSPIRIS RESILIA Aortic Valve

13.1.3 Key Indications
13.1.4 Pipeline Programs and Clinical Studies
13.1.5 Financial and Strategic Highlights

13.2 Medtronic
- 13.2.1 Company Overview
- 13.2.2 Approved Products

CoreValve Evolut Platform

Harmony Transcatheter Pulmonary Valve

13.2.3 Key Indications
13.2.4 Pipeline Programs and Clinical Studies
13.2.5 Financial and Strategic Highlights

13.3 Abbott Laboratories
- 13.3.1 Company Overview
- 13.3.2 Approved Products

Epic Mitral and Aortic Valves

Portico Transcatheter Aortic Valve System

Navitor TAVI System

13.3.3 Key Indications
13.3.4 Pipeline Programs and Clinical Studies
13.3.5 Financial and Strategic Highlights

13.4 Boston Scientific
- 13.4.1 Company Overview
- 13.4.2 Approved Products

ACURATE neo2 Aortic Valve System

13.4.3 Key Indications
13.4.4 Pipeline Programs and Clinical Studies
13.4.5 Financial and Strategic Highlights

13.5 Artivion
- 13.5.1 Company Overview
- 13.5.2 Approved Products

On-X Mechanical Heart Valve

13.5.3 Key Indications
13.5.4 Pipeline Programs and Clinical Studies
13.5.5 Financial and Strategic Highlights

13.6 LivaNova
- 13.6.1 Company Overview
- 13.6.2 Approved Products

Bicarbon Mechanical Heart Valves

13.6.3 Key Indications
13.6.4 Pipeline Programs and Clinical Studies
13.6.5 Financial and Strategic Highlights

13.7 JenaValve Technology
- 13.7.1 Company Overview
- 13.7.2 Approved Products and Investigational Systems

JenaValve Trilogy Heart Valve System

13.7.3 Key Indications
13.7.4 Pipeline Programs and Clinical Studies
13.7.5 Financial and Strategic Highlights

13.8 Meril Life Sciences
- 13.8.1 Company Overview
- 13.8.2 Approved Products

Myval Transcatheter Heart Valve

13.8.3 Key Indications
13.8.4 Pipeline Programs and Clinical Studies
13.8.5 Financial and Strategic Highlights

13.9 Corcym
- 13.9.1 Company Overview
- 13.9.2 Approved Products

Perceval Sutureless Heart Valve

13.9.3 Key Indications
13.9.4 Pipeline Programs and Clinical Studies
13.9.5 Financial and Strategic Highlights

13.10 Braile Biomedica
- 13.10.1 Company Overview
- 13.10.2 Approved Products

Transcatheter Aortic Valve Systems

Surgical Bioprosthetic Heart Valves

13.10.3 Key Indications
13.10.4 Pipeline Programs and Clinical Studies
13.10.5 Financial and Strategic Highlights

14. Future Outlook

14.1 Future Market Evolution
14.2 Emerging Technology Trends
14.3 Structural Heart Intervention Outlook
14.4 AI and Digital Integration Outlook
14.5 Competitive Outlook
14.6 Future Regulatory Trends
14.7 Long-Term Market Forecast

15. Methodology

15.1 Research Methodology
15.2 Secondary Research Sources
15.3 Primary Research Methodology
15.4 Market Size Estimation Approach
15.5 Forecasting Methodology
15.6 Data Triangulation
15.7 Assumptions and Limitations
15.8 Abbreviations and Definitions